Lumos Pharma Shares Outstanding vs. Cash Per Share
| LUMO Stock | USD 4.32 0.02 0.47% |
For Lumos Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lumos Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lumos Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lumos Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lumos Pharma over time as well as its relative position and ranking within its peers.
Lumos |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lumos Pharma Cash Per Share vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lumos Pharma's current stock value. Our valuation model uses many indicators to compare Lumos Pharma value to that of its competitors to determine the firm's financial worth. Lumos Pharma is rated below average in shares outstanding category among its peers. It is currently regarded as number one stock in cash per share category among its peers . The ratio of Shares Outstanding to Cash Per Share for Lumos Pharma is about 911,340 . At this time, Lumos Pharma's Cash Per Share is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lumos Pharma's earnings, one of the primary drivers of an investment's value.Lumos Cash Per Share vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Lumos Pharma |
| = | 8.65 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Lumos Pharma |
| = | 9.49 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Lumos Cash Per Share Comparison
Lumos Pharma is currently under evaluation in cash per share category among its peers.
Lumos Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lumos Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lumos Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Lumos Pharma's change in net profit over the period of time. It can combine multiple indicators of Lumos Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -36.6 M | -38.4 M | |
| Income Before Tax | -34.1 M | -35.8 M | |
| Total Other Income Expense Net | 2.6 M | 2.7 M | |
| Net Loss | -34 M | -35.7 M | |
| Income Tax Expense | -29 K | -30.4 K | |
| Net Loss | -32.8 M | -34.5 M | |
| Non Operating Income Net Other | 7.7 M | 8.1 M | |
| Net Loss | -35.7 M | -37.5 M | |
| Interest Income | 2.1 M | 2.2 M | |
| Net Interest Income | 2.1 M | 1.1 M | |
| Change To Netincome | 2.1 M | 2 M | |
| Net Loss | (4.18) | (4.39) | |
| Income Quality | 0.91 | 0.82 | |
| Net Income Per E B T | 1.00 | 1.03 |
Lumos Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lumos Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lumos Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lumos Pharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Lumos Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
Use Investing Themes to Complement your Lumos Pharma position
In addition to having Lumos Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Trump Equities Thematic Idea Now
Trump Equities
Stocks that have significantly increased in valuation since Trump was elected president of the United States. The Trump Equities theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Trump Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
To fully project Lumos Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lumos Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lumos Pharma's income statement, its balance sheet, and the statement of cash flows.